Mandate

Vinge has advised Egetis Therapeutics in connection with directed share issuances

October 03, 2024

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with directed share issuances whereby Egetis Therapeutics receives gross proceeds of SEK 300 million.

The share issuances were directed to a number of international and Swedish institutional investors on the basis of an accelerated bookbuilding process. One of the issuances is subject to approval by an extraordinary general meeting as well as approval and publication of a prospectus.

Vinge’s team consisted of Dain Hård Nevonen, Lorin Arabi and Karin Karsten.

Related

Vinge advises Platzer in conjunction with the sale of a school property in Gothenburg

Vinge has advised Platzer Fastigheter AB in connection with the sale of a school property situated in Södra Änggården, Gothenburg. The property, which was sold as a corporate transaction, has a value of SEK 552 million. The sale is part of Platzer's strategy to develop and optimise its property portfolio.
January 17, 2025

Vinge advises Qben Infra in connection with issuance of senior, unsecured bonds and early redemption

Vinge has advised Qben Infra AB in connection with its issuance of senior, unsecured bonds in an amount of SEK 500,000,000 (within a framework of SEK 600,000,000) and the parallel early redemption by its subsidiary ININ Group AS in respect of its previously issued senior secured bonds due 2027.
January 16, 2025

Vinge Represents Ellevio in the Acquisition of Markbygden Net Väst AB

Vinge represents Ellevio in the acquisition of Markbygden Net Väst AB, a network company that connects to the national grid via Svenska kraftnät's station in Trolltjärn outside Arvidsjaur, from Enercon.
January 16, 2025